Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
NCT ID: NCT02228304
Last Updated: 2022-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
42 participants
INTERVENTIONAL
2014-09-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Clinical Hypotheses:
* NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the prevention of vision loss due to recurrent CNV secondary to AMD
* NT-503-3 ECT has an acceptable safety profile
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447980
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
NCT00447954
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT00447993
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT04339764
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
NCT06394232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NT-503-3 ECT implantation
NT-503-3 ECT implantation
NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
Eylea® injected intravitreally every 8 weeks
Eylea® injected intravitreally every 8 weeks
Eylea® injected intravitreally administered every 8 weeks
The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NT-503-3 ECT implantation
NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
Eylea® injected intravitreally administered every 8 weeks
The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prior Intravitreal Anti-VEGF injections
Exclusion Criteria
* Significant Scar and/or, fibrosis
* Suspected polypoidal choroidopathy, or pigment epithelial tears or rips
* Inadequate response to anti-VEGF therapy
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neurotech Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Johnson, MB, ChB
Role: STUDY_CHAIR
Neurotech Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Associated Retina Consultants, Ltd.
Phoenix, Arizona, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
University of California, Irvine, The Gavin Herbert Eye Institute
Irvine, California, United States
Jacobs Retina Center at UCSD
La Jolla, California, United States
Colorado Retina Associates
Golden, Colorado, United States
Retina Health Center
Fort Myers, Florida, United States
National Ophthalmic Research Institute
Fort Myers, Florida, United States
Center for Retina and Macular Disease
Winter Haven, Florida, United States
Southeast Retina Center, PC
Augusta, Georgia, United States
Georgina Retina, P.C.
Marietta, Georgia, United States
Illinois Retina Associates, S.C.
Joliet, Illinois, United States
Illinois Retina Associates
Oak Park, Illinois, United States
Retina Associates of Kentucky
Lexington, Kentucky, United States
The Retina Group of Washington
Chevy Chase, Maryland, United States
Cumberland Valley Retina Consultants, PC
Hagerstown, Maryland, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan, United States
William Beaumont Hospital-Ophthalmology Research
Royal Oak, Michigan, United States
Lifelong Vision Foundation
Chesterfield, Missouri, United States
Sierra Eye Associates
Reno, Nevada, United States
Retina Center of New Jersey, LLC
Bloomfield, New Jersey, United States
NJ Retina
New Brunswick, New Jersey, United States
Western Carolina Retinal Associates
Asheville, North Carolina, United States
Wake Forest Baptist Health Eye Center
Winston-Salem, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Retina Northwest, PC
Portland, Oregon, United States
Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Palmetto Retina Center, LLC
Florence, South Carolina, United States
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States
Valley Retina Institute, PA
McAllen, Texas, United States
Medical Center Ophthalmology Associates
San Antonio, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Soroka Medical Center
Beersheba, , Israel
Hadassah-Hebrew University Medical Center
Jerusalem, , Israel
Meir Medical Center
Kfar Saba, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Kaplan Medical Center
Rehovot, , Israel
Sourasky Medical Center,
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NT-503-3-AMD-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.